Yang S-C, Lai Y-Y, Huang M-C, Tsai C-S, Wang J-L
1 Department of Nursing, National Tainan Institute of Nursing, Tainan, Taiwan.
2 Department of Applied Cosmetology, National Tainan Institute of Nursing, Tainan, Taiwan.
Lupus. 2018 Oct;27(11):1819-1827. doi: 10.1177/0961203318792352. Epub 2018 Aug 13.
Objective This study investigated whether the incidence of opportunistic infection differed in systemic lupus erythematosus patients who received different doses of corticosteroids. Methods We included patients with diagnosed systemic lupus erythematosus from 1997 to 2010 using Taiwan national health insurance data. The index day for systemic lupus erythematosus patients was 3 months after the systemic lupus erythematosus diagnosis. A non-steroid cohort was matched 4:1 with the steroid cohort according to age, sex and index day. The end of the follow-up period was the day of opportunistic infection diagnosis, 1 year after the index day, or death. Results The overall cumulative incidence of opportunistic infection was 136-fold higher in the steroid cohort than in the non-steroid cohort. The adjusted hazard ratio for developing mycobacterium infection in the steroid cohort was 11, and the adjusted hazard ratio for developing herpes zoster was 43.6 compared to the non-steroid cohort after adjusting for immunosuppressive agents and comorbidities. The adjusted hazard ratio value for opportunistic infection was 1.40 (95% confidence interval (CI) 0.78-2.51) for a daily prednisone-equivalent dose of 7.5-15 mg, 1.72 (95% CI 1.02-2.91) for 15-30 mg, 1.96 (95% CI 1.17-3.28) for 30-60 mg and 2.24 (95% CI 1.26-4.00) for over 60 mg compared with low-dose steroids (<7.5 mg). Conclusion This study confirmed that the risk of opportunistic infection is higher in systemic lupus erythematosus patients treated with steroids in the first 3 months after diagnosis versus those not treated with steroids. Medium and high doses were associated with a higher risk of opportunistic infection compared with low doses. However, there was no controlling for disease activity, making it hard to know if increases in infection were due to disease itself or corticosteroids.
目的 本研究调查了接受不同剂量皮质类固醇治疗的系统性红斑狼疮患者机会性感染的发生率是否存在差异。方法 我们使用台湾国民健康保险数据纳入了1997年至2010年确诊为系统性红斑狼疮的患者。系统性红斑狼疮患者的索引日为系统性红斑狼疮诊断后3个月。非类固醇队列根据年龄、性别和索引日与类固醇队列按4:1进行匹配。随访期结束为机会性感染诊断日、索引日后1年或死亡日。结果 类固醇队列中机会性感染的总体累积发生率比非类固醇队列高136倍。在调整免疫抑制剂和合并症后,类固醇队列中发生分枝杆菌感染的调整后风险比为11,发生带状疱疹的调整后风险比为43.6,与非类固醇队列相比。与低剂量类固醇(<7.5mg)相比,每日泼尼松等效剂量为7.5 - 15mg时机会性感染的调整后风险比值为1.40(95%置信区间(CI)0.78 - 2.51),15 - 30mg时为1.72(95%CI 1.02 - 2.91),30 - 60mg时为1.96(95%CI 1.17 - 3.28),超过60mg时为2.24(95%CI 1.26 - 4.00)。结论 本研究证实,在诊断后的前3个月接受类固醇治疗的系统性红斑狼疮患者比未接受类固醇治疗的患者发生机会性感染的风险更高。与低剂量相比,中高剂量与机会性感染的风险更高相关。然而,未对疾病活动进行控制,因此难以确定感染增加是由于疾病本身还是皮质类固醇。